## Iridian UCITS Fund plc

**Audited Annual Financial Statements** 

For the financial year ended 31 December 2020

**Registration Number: 534929** 

32 Molesworth Street Dublin 2 Ireland

## TABLE OF CONTENTS

	Page
DIRECTORY	1
DIRECTORS' REPORT	3
DEPOSITARY'S REPORT	6
INVESTMENT MANAGER'S REPORT	7
INDEPENDENT AUDITORS' REPORT	9
SCHEDULE OF INVESTMENTS	12
STATEMENT OF FINANCIAL POSITION	14
STATEMENT OF COMPREHENSIVE INCOME	15
STATEMENT OF CHANGES IN NET ASSETS ATTRIBUTABLE TO HOLDERS OF PARTICIPATING SHARES	16
STATEMENT OF CASH FLOWS	17
NOTES TO THE FINANCIAL STATEMENTS	18
SCHEDULE OF SIGNIFICANT CHANGES IN THE PORTFOLIO	35
APPENDIX I (UNAUDITED) ADDITIONAL INFORMATION FOR INVESTORS IN SWITZERLAND	36
APPENDIX II (UNAUDITED) INVESTMENT MANAGER REMUNERATION DISCLOSURES	38

#### **DIRECTORY**

**Directors of the Company** 

James Fergus McKeon (Ireland)<sup>(1)</sup> Gerald Brady (Ireland) (Chairman)<sup>(1)</sup> Jeffrey M. Elliott (United States) Lane S. Bucklan (United States)

All the Directors are non-executive

**Investment Manager, Distributor and Promoter** 

Iridian Asset Management LLC 276 Post Road West Westport CT 06880-4704

Administrator

United States

SEI Investments - Global Fund Services Limited Styne House Upper Hatch Street

Dublin 2 Ireland

**Independent Auditors** 

Deloitte Ireland LLP
Chartered Accountants and Statutory

Audit Firm,

Deloitte & Touche House

Earlsfort Terrace

Dublin 2 Ireland

**Governance Services Provider** 

Bridge Consulting Ferry House 48-53 Mount Street Lower

Dublin 2

D02 PT98 Ireland

Spanish Distributor (4)

Selección e Inversión de Capital Global, Agencia de Valores, S.A. Calle Maria Francisca, 9

Madrid - 28002

**Registered Office** 

MFD Secretaries Limited 32 Molesworth Street

Dublin 2 Ireland

**Company Secretary** 

MFD Secretaries Limited 32 Molesworth Street

Dublin 2 Ireland

**Depositary** 

SEI Investments - Depositary and Custodial Services

(Ireland) Limited Styne House Upper Hatch Street

Dublin 2 Ireland

**Legal Advisers to the Company** 

Maples and Calder (Ireland) LLP

75 St. Stephen's Green

Dublin 2 Ireland

Swiss Paying Agent & Swiss Representative<sup>(2) (3)</sup>

Société Générale Paris Zurich Branch, Talacker 50

P.O. Box 5070 CH-8021 Zürich Switzerland

**UK Facilities Agent** 

Maples Fiduciary Services (UK) Limited

11<sup>th</sup> Floor

200 Aldersgate Street London EC 1A 4HD United Kingdom

### **DIRECTORY** – (continued)

- (1) Independent non-executive director.
- (2) Shareholders may obtain the Prospectus, the Key Investor Information Document, the latest annual and semi-annual reports, the changes in the composition of the portfolio during the reporting period, the statement of purchases and sales and copies of the Memorandum and Articles of Association free of charge from the registered office of the Company or the local representatives in the countries where the Company is registered and in Switzerland at the office of the Representative at Société Générale Paris, Zurich Branch, Talacker 50, P.O.B. 5070, CH-8021 Zürich. The issue and the redemption prices of the shares of each Fund of the Company will be published daily on the electronic platform http://www.fundinfo.com.

The annual financial statements (the "Report and Accounts") may be translated into other languages. Any such translation shall only contain the same information and have the same meaning as the English language Report and Accounts. To the extent that there is any inconsistency between the English language Report and Accounts and the Report and Accounts in another language, the English language Report and Accounts will prevail, except to the extent (and only to the extent) that it is required by law of any jurisdiction where the Shares are sold, that in an action based upon disclosure in a Report and Accounts in a language other than English, the language of the Report and Accounts on which such action is based shall prevail. Any disputes as to the terms of the Report and Accounts, regardless of the language of the Report and Accounts, shall be governed by and construed in accordance with the laws of Ireland.

- (3) The appointment was effective up to and including 31 December 2020 and immediately terminated thereafter following withdrawal of marketing activities in Switzerland.
- (4) The appointment was effective up to and including 21 February 2020 and immediately terminated thereafter following withdrawal of marketing activities in Spain.

### **DIRECTORS' REPORT**

### For the financial year ended 31 December 2020

The Directors submit their report together with the audited financial statements of Iridian UCITS Fund plc (the "Company") for the financial year ended 31 December 2020.

### Statement of Directors' responsibilities for the Financial Statements

Irish company law requires the Directors to prepare financial statements for each financial year which give a true and fair view of the assets, liabilities and financial position of the Company and of its profit or loss for that financial year.

In preparing the financial statements, the Directors are required to:

- select suitable accounting policies and then apply them consistently;
- make judgements and estimates that are reasonable and prudent;
- state whether the financial statements have been prepared in accordance with applicable accounting standards, identify those standards, and note the effect and the reasons for any material departure from those standards; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Company will continue in business.

The Directors are responsible for ensuring that the Company keeps or causes to be kept adequate accounting records which correctly record and explain the transactions of the Company and which disclose with reasonable accuracy at any time the assets, liabilities, financial position and profit or loss of the Company and enable them to ensure that the financial statements and Directors' Report are prepared in accordance with International Financial Reporting Standards ("IFRS") as adopted by the European Union and comply with the Companies Act 2014 (the "Companies Act 2014"), the European Communities (Undertakings for Collective Investment in Transferable Securities) Regulations, 2011 (as amended) (the "UCITS Regulations") and the Central Bank (Supervision and Enforcement) Act 2013 (Section 48(1)) (Undertakings for Collective Investment in Transferable Securities) Regulations, 2019 (the "Central Bank UCITS Regulations") and enable the financial statements to be audited. They are also responsible for safeguarding the assets of the Company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities. The responsibility for safeguarding the assets of the Company has been delegated to the Depositary.

### **Business review and principal activities**

The Company is an umbrella type open-ended Investment Company with variable capital and limited liability incorporated on 4 November 2013 under the laws of Ireland with segregated liability between its sub-funds. The Company is authorised in Ireland by the Central Bank of Ireland pursuant to the UCITS Regulations and the Central Bank UCITS Regulations. The Company currently has one active sub-fund, Iridian U.S. Equity Fund (the "Sub-Fund"). The business of the Company and of the Sub-Fund is reviewed in detail in the Investment Manager's Report on page 7.

### Review of Development of the business and future developments

The change in the net asset value for the financial year is a key indicator of the performance of the Company. A detailed review of the business and future developments is included in the Investment Manager's Report on page 7.

### Risk management objectives and policies

The principal risks and uncertainties which the Company face relate to the use of financial instruments and are listed in Note 12 "Risks associated with financial instruments". The investment objective of the Company is disclosed in Note 1 "Organisation".

#### Results

The results of operations are set out in the Statement of Comprehensive Income on page 15.

### Events during the financial year

Significant events during the financial year are disclosed in Note 15 "Events during the reporting financial year".

### **DIRECTORS' REPORT (continued)**

### For the financial year ended 31 December 2020

### Events since the financial year end

Significant events since the financial year end are disclosed in Note 16 "Events after the reporting financial year end".

#### Dividends

No dividend was paid or proposed during the financial year.

#### **Political Donations**

The Company made no political donations during the financial year.

#### Directors

The Directors that served during the financial year are listed on page 1. There were no changes to the Directors during the financial year.

### **Directors' and Company Secretary's Interests**

At the date of this Report, the Directors, the Company Secretary or connected persons have no beneficial or non-beneficial interests in the shares of the Company.

### **Statement of Corporate Governance**

The Irish Funds Association ("IF") published a corporate governance code ("IF Code") in December 2011 that may be adopted on a voluntary basis by Irish authorised collective investment schemes. The IF Code has been adopted by the Company with an effective date of 16 December 2013. During the financial year under review, the Company has met the requirements of the IF Code.

#### **Connected Persons**

The Directors are satisfied that there are adequate arrangements in place to ensure that all transactions with connected persons, namely the Investment Manager or Depositary; and the delegates or sub-delegates of the Investment Manager or Depositary (excluding any non-group company sub-custodians appointed by a depositary); and any associated or group company of the Investment Manager, Depositary, delegate or sub-delegate, are conducted at arm's length and in the best interests of the shareholders as required by the Central Bank UCITS Regulations, Sections 42 and 43. The Directors are satisfied that transactions with connected persons entered into during the financial year were carried out on this basis.

Shareholders should be aware that not all "connected persons" as defined by the Central Bank UCITS Regulations are "related parties" as defined by IAS 24, "Related Party Disclosures".

### **Accounting Records**

The Directors have ensured that the adequate accounting records requirements under Sections 281 to 285 of the Companies Act 2014 have been complied with by outsourcing this function to a specialist provider of such services. The accounting records are held by SEI Investments – Global Fund Services Limited or at the Company's registered office which is 32 Molesworth Street, Dublin 2, Ireland.

### **Directors' Compliance Statement**

The Directors acknowledge that they are responsible for securing the company's compliance with the relevant obligations as set out in Section 225 of the Companies Act 2014.

The Directors confirm that:

- 1) A compliance policy document has been drawn up that sets out policies, that in our opinion are appropriate to the company, respecting compliance by the company with its relevant obligations;
- 2) Appropriate arrangements or structures are in place that are, in our opinion, designed to secure material compliance with the company's relevant obligations; and
- 3) During the financial year, the arrangements or structures referred to in (2) have been reviewed.

The Directors confirm that they have complied with the above requirements in preparing the Company's financial statements.

# DIRECTORS' REPORT (continued) For the financial year ended 31 December 2020

### Auditors

Deloitte Ireland LLP. Chartered Accountants and Statutory Audit Firm, have indicated their willingness to continue in office in accordance with Section 383(2) of the Companies Act 2014.

### Establishment of an audit committee

The Directors had resolved not to establish an audit committee pursuant to section 167(2) of the Companies Act 2014, and it was noted that this had been decided on the basis of the following:

- 1) The nature, scale and complexity of the Company's business range of services and activities undertaken in the course of that business;
- 2) The resources available to the Company and the resources and expertise of the various third parties engaged to support the Company and carry out certain functions on its behalf; and
- 3) The procedures in place for the review, approval and circulation of the audited financial accounts and statements which were appropriate for a self-managed company pursuant to the UCITS Regulations.

### Statement of Relevant Audit Information

As required by Section 330 of the Companies Act 2014, the following applies in the case of each person who was a Director of the Company, as disclosed on page 1, at the time that this report is approved:

- 1) As far as the Directors are aware, there is no relevant audit information of which the Company's statutory auditors are unaware; and
- 2) The Directors have taken all the steps that ought to have been taken by the Directors in order to make themselves aware of any relevant audit information and to establish that the Company's statutory auditors are aware of that information.

On Behalf of the Board of Directors

James Fergus McKeon

Date: 27 April 2021

### DEPOSITARY'S REPORT TO THE SHAREHOLDERS OF IRIDIAN UCITS FUND PLC

We, SEI Investments-Depositary and Custodial Services, appointed Depositary to Iridian UCITS Fund PLC ("the Company") provide this report solely in favour of the investors of the Company as a body for the year ended 31 December 2020 ("the Accounting Period"). This report is provided in accordance with the UCITS Regulations – European Communities (Undertakings for Collective Investment in Transferable Securities) Regulations 2011 (SI No 352 of 2011) as amended, ("the UCITS Regulations"). We do not, in the provision of this report, accept nor assume responsibility for any other purpose or person to whom this report is shown.

In accordance with our Depositary obligation as provided for under the UCITS Regulations, we have enquired into the conduct of the Company for the Accounting Period and we hereby report thereon to the investors of the Company as follows;

We are of the opinion that the Company has been managed during the Accounting Period, in all material respects:

- (i) in accordance with the limitations imposed on the investment and borrowing powers of the Company by the constitutional documents and by the UCITS Regulations; and
- (ii) otherwise in accordance with the provisions of the constitutional document and the UCITS Regulations.

For and on behalf of SEI Investments – Depositary and Custodial Services (Ireland) Limited

**Date:** 27 April 2021

### INVESTMENT MANAGER'S REPORT For the financial year ended 31 December 2020

During the calendar period from 1 January 2020 to 31 December 2020, the Sub-Fund's Class I USD (A) shares returned 19.26% (net-of-fees), compared to the benchmark, the Russell 1000 Index, which retuned 20.96%.

### **Performance Review**

The calendar year 2020 saw strong positive performance from both Iridian and the market despite the very significant volatility the markets exhibited during 2020. When the impact of COVID became apparent in Q1 2020, we performed an exhaustive reevaluation of the entire portfolio. We looked at both (i) the temporal impact on operations, and (ii), the long-term competitive opportunity. We moved on from those stocks that we felt were long term impaired and committed to ideas that had high quality in their businesses, and collectively gave a strong foundation of balance to the portfolio. We now know that this assessment was extremely predictive of portfolio performance post the March collapse in stock prices with the onset of COVID. COVID accelerated the widespread usage of remote technology that was already available. Zoom became a verb almost overnight, but the technology would have gained a deserved prominence in any case. The common thread we saw was that companies that could use technology to quickly adapt their businesses to the changed environment thrived while others lagged. In essence, the strong became stronger while the weak withered.

With this framework in mind, we also sought to position the portfolio to benefit from several powerful secular tailwinds emerging in 2020, and that we believe will persist in 2021 and beyond:

- Data and AI Ascendancy
- 5G Revolution
- Cloud proliferation
- Semi-conductor revolution
- Security primacy
- Greening of energy
- Biotech revolution

\_

Set against these strong secular forces, we are also giving due consideration to two cyclical factors at play:

- Epicenter recovery businesses that suffered from COVID have cut costs substantially and will come back strongly as we return to normal. In these cases, 'less bad is good'. However, this scenario could deteriorate if mutant variants of COVID prove impervious to inoculation.
- Monetary policy cycle Fed Chair Powell has clearly stated interest rates will remain low until the labor market recovers and inflation is 2 percent and heading higher. Additionally, the fiscal outlook appears to favor substantial stimulus. What is unclear is how the patient, the economy, will respond to this unprecedented combination of monetary accommodation and fiscal stimulus. Could inflationary pressure reappear or stay nascent? We want to be sure the portfolio could prosper in either eventuality.

Looking to the year ahead, the biggest debate will likely move past COVID, and focus on how we return to a world of financial normalcy. The pivotal concern will be on how the market will react to a tapering of monetary accommodation. In previous years, any hint of a Fed taper has led to increased market volatility. Our instinctual view is to expect the market to consolidate in 2021, following the strong performance of the past two years. However low interest rates could generate further multiple upsides. That coupled with above normal GDP growth and strong earnings could lead to favorable returns.

# **INVESTMENT MANAGER'S REPORT (CONTINUED)**For the financial year ended 31 December 2020

As we look at our portfolio, we believe our companies, in general, are stronger post-COVID, which leaves us cautiously optimistic for our subset of stocks. Additionally, we will continue to strive to maintain balance regarding macro-outcomes. We do not want to overweight a recovery bet, but nor do we want to adopt an excessively defensive posture. Overall, we presume a return to a sense of normalcy, but still aim to maintain a durability within the portfolio, so that we are positioned for 'come what may'. We will continue to use our change focus to identify situations where corporate change will catalyze significant value creation.

As always, thank you for your continued support.

Iridian Asset Management LLC 12 February 2021



## INDEPENDENT AUDITOR'S REPORT TO THE SHAREHOLDERS OF IRIDIAN UCITS FUND PLC

### Report on the audit of the financial statements

### Opinion on the financial statements of Iridian UCITS Fund plc ("the company")

In our opinion the financial statements:

- give a true and fair view of the assets, liabilities and financial position of the company as at 31 December 2020 and of the profit for the financial year then ended; and
- have been properly prepared in accordance with the relevant financial reporting framework, the applicable Regulations and, in particular, with the requirements of the Companies Act 2014.

The financial statements we have audited comprise:

- the Statement of Comprehensive Income;
- the Statement of Financial Position;
- the Statement of Changes in Net Assets attributable to holders of Patricipating Shares;
- the Statement of Cash Flows; and
- the related notes 1 to 18, including a summary of significant accounting policies as set out in note 2.

The relevant financial reporting framework that has been applied in their preparation is the Companies Act 2014 and International Financial Reporting Standards (IFRS) as adopted by the European Union ("the relevant financial reporting framework").

The applicable regulations that have been applied in their preparation is [the European Communities (Undertakings for Collective Investment in Transferable Securities) Regulations, 2011 and Central Bank (Supervision and Enforcement) Act 2013 (Section 48(1)) (Undertakings for Collective Investment in Transferable Securities) Regulations, 2019 ("the applicable Regulations").

#### Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (Ireland) (ISAs (Ireland)) and applicable law. Our responsibilities under those standards are described below in the "Auditor's responsibilities for the audit of the financial statements" section of our report.

We are independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in Ireland, including the Ethical Standard issued by the Irish Auditing and Accounting Supervisory Authority, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

### Conclusions relating to going concern

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

Continued on next page/

## Deloitte.

/Continued from previous page

## INDEPENDENT AUDITOR'S REPORT TO THE SHAREHOLDERS OF IRIDIAN UCITS FUND PLC

#### Other information

The other information comprises the information included in the Annual Financial Statements, other than the financial statements and our auditor's report thereon. The directors are responsible for the other information contained within the Annual Financial Statements. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

### Responsibilities of directors

As explained more fully in the Statement of Directors' responsibilities for the Financial Statements, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view and otherwise comply with the Companies Act 2014, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.

### Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (Ireland) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with ISAs (Ireland), we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and
  perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a
  basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting
  from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal
  control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the directors.

Continued on next page/

## Deloitte.

/Continued from previous page

# INDEPENDENT AUDITOR'S REPORT TO THE SHAREHOLDERS OF IRIDIAN UCITS FUND PLC

- Conclude on the appropriateness of the directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of the auditor's report. However, future events or conditions may cause the entity (or where relevant, the group) to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that the auditor identifies during the audit.

#### Report on other legal and regulatory requirements

### Opinion on other matters prescribed by the Companies Act 2014

Based solely on the work undertaken in the course of the audit, we report that:

- We have obtained all the information and explanations which we consider necessary for the purposes of our audit.
- In our opinion the accounting records of the company were sufficient to permit the financial statements to be readily and properly audited.
- The financial statements are in agreement with the accounting records.
- In our opinion the information given in the directors' report is consistent with the financial statements and the directors' report has been prepared in accordance with the Companies Act 2014.

### Matters on which we are required to report by exception

Based on the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the directors' report.

We have nothing to report in respect of the provisions in the Companies Act 2014 which require us to report to you if, in our opinion, the disclosures of directors' remuneration and transactions specified by law are not made.

### Use of our report

This report is made solely to the company's shareholders, as a body, in accordance with Section 391 of the Companies Act 2014. Our audit work has been undertaken so that we might state to the company's shareholders those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's shareholders as a body, for our audit work, for this report, or for the opinions we have formed.

Christian MacManus

For and on behalf of Deloitte Ireland LLP Chartered Accountants and Statutory Audit Firm Deloitte & Touche House, Earlsfort Terrace, Dublin 2

Date: 29 April 2021

### SCHEDULE OF INVESTMENTS As at 31 December 2020

## Iridian U.S. Equity Fund

Train C.S. Equity Fund	Chanas	Fair Value	0/ NI A X7
Equities	Shares	US\$	%NAV
<u>Canada</u>			
Restaurant Brands International Inc.	43,541		2.37%
Total Canada		2,660,791	2.37%
<u>Ireland</u>			
Aon Plc.	15,351	3,243,206	2.88%
Total Ireland	13,331	3,243,206	2.88%
Town House		0,210,200	2.0070
Singapore			
Flex Ltd.	294,006	5,286,228	4.70%
Total Singapore	-	5,286,228	4.70%
<u>United States</u>	10 55	2110201	1.010/
Alexion Pharmaceuticals Inc.	13,757	2,149,394	1.91%
Anthem Inc.	9,943	3,192,598	2.84%
Ashland Global Holdings Inc.	9,457	748,994	0.67%
AutoZone Inc.	3,243	3,844,382	3.42%
Axsome Therapeutics, Inc.	42,440	3,457,587	3.08%
Ball Corp.	17,455	1,626,457	1.45%
Beacon Roofing Supply, Inc.	53,178	2,137,224	1.90%
Bridgebio Pharma Inc.	11,503	817,978	0.73%
Change Healthcare Inc.	67,816	1,264,768	1.12%
Charles River Laboratories International, Inc.	5,988	1,496,162	1.33%
Colony Capital Inc.	390,378	1,877,718	1.67%
Cree Inc.	26,088	2,762,719	2.46%
Dell Technologies Inc.	30,875	2,262,829	2.01%
Element Solutions LLC	34,262	607,465	0.54%
Entegris, Inc.	12,954	1,244,879	1.11%
Finserv Acquisition Corp.	86,258	1,078,225	0.96%
Frontdoor Inc.	52,035	2,612,677	2.32%
Hilton Worldwide Holdings Inc.	10,477	1,165,671	1.04%
IAC/InterActiveCorp.	11,989	2,270,117	2.02%
Intercontinental Exchange Inc.	27,625	3,184,886	2.83%
KKR & Co. Inc.	35,523	1,438,326	1.28%
L3Harris Technologies, Inc.	15,605	2,949,657	2.62%
Laboratory Corp of America Holdings	20,448	4,162,190	3.70%
Lithia Motors Inc.	4,548	1,331,063	1.18%
Lyft Inc.	22,121	1,086,805	0.97%
Marriott Vacations Worldwide Corporation	21,691	2,976,439	2.65%
Martin Marietta Materials Inc.	4,328	1,229,022	1.09%
Molina Healthcare Inc.	11,847	2,519,620	2.24%
Morningstar Inc.	3,057	707,909	0.63%
Post Holdings Inc.	41,270	4,168,683	3.71%
Qorvo Inc.	20,487	3,406,373	3.03%
S&P Global Inc.	6,353	2,088,422	1.86%
Sherwin-Williams Co.	2,352	1,728,508	1.54%
Splunk Inc.	12,367	2,101,030	1.87%

# SCHEDULE OF INVESTMENTS (CONTINUED) As at 31 December 2020

## Iridian U.S. Equity Fund – (continued)

	Fair Value		
	Shares	US\$	%NAV
Equities (continued)			
United States (continued)			
Stericycle, Inc.	23,476	1,627,591	1.45%
Terminix Global Holdings Inc.	79,698	4,065,395	3.62%
Uber Technologies Inc.	48,126	2,454,426	2.18%
Univar Inc.	129,231	2,456,681	2.19%
Vertiv Holdings Co	57,346	1,070,650	0.95%
Viatris Inc.	150,241	2,815,516	2.50%
Visteon Corp.	13,352	1,675,943	1.49%
Wyndham Destinations Inc.	89,202	4,001,602	3.56%
Wynn Resorts Ltd	24,634	2,779,455	2.47%
Zynga Inc.	390,961	3,858,786	3.42%
Total United States		98,502,822	87.61%
Total Equities		109,693,047	97.56%

### Forward Foreign Currency Contracts

		Nominal	Nominal Amount		Fair Value	
Currency	Counterparty	Amount Bought	Sold	Maturity		NAV%
Buy GBP/Sell USD	Brown Brothers Harriman & Co.	36,974	50,059	04-Jan-21	505	0.00%
Buy GBP/Sell USD	Brown Brothers Harriman & Co.	240,111	326,900	05-Jan-21	1,465	0.00%
Unrealised gains of	n Forward Foreign Currency C	Contracts			1,970	0.00%
Total Financial Ass	sets At Fair Value Through Pro	fit Or Loss			109,695,017	97.56%
Buy USD/Sell GBP	Brown Brothers Harriman & Co.	49,882	36,974	04-Jan-21	(682)	0.00%
Buy USD/Sell GBP	Brown Brothers Harriman & Co.	327,368	240,111	05-Jan-21	(998)	0.00%
Unrealised losses of	on Forward Foreign Currency (	Contracts			(1,680)	0.00%
Total Financial Lia	abilities At Fair Value Through	Profit Or Loss			(1,680)	0.00%
Cash and Cash Equiv	alents				3,194,743	2.84%
Other Net Liabilities	5				(454,546)	(0.40%)
Net Assets Attribut	able To Holders Of Participati	ng				
Shares (Dealing NA	AV)				112,433,534	100.00%

# STATEMENT OF FINANCIAL POSITION As at 31 December 2020

	Note	Iridian U.S. Equity Fund 31-Dec-2020 US\$	Iridian U.S. Equity Fund 31-Dec-2019 US\$
Assets Financial assets at fair value through profit or loss Cash and cash equivalents Subscriptions receivable Dividends receivable Total Assets	2,13	109.695.017 3,194,743 376.959 17,603 113,284,322	208,186,720 6,556,333 41,035 11,774 214,795,862
Liabilities Financial liabilities at fair value through profit or loss Securities purchased payable Redemptions payable	2,13	1,680 170,338 509,419	1,291 214,502 288,032
Investment management fee payable	6	84,804	192,651
Administration fee payable Audit fee payable Legal fee payable	6	28,164 28,000 5,000	47,863 30,083 7,268
Depositary fee payable Other accrued expenses Total Liabilities	6	3.178 20,205 850,788	5,196 63,472 850,358
Net assets attributable to holders of participating shares	5	112,433,534	213,945,504

On Behalf of the Board of Directors

James Fergus McKeon

Date: 27 April 2021

# STATEMENT OF COMPREHENSIVE INCOME For the financial year ended 31 December 2020

U.S. Equity Fund 1-Jan-2020 to 1-Jan-2019 31-Dec-2020 31-Dec-2010	to 19 S\$
31-Dec-2020 31-Dec-201	19 S\$
	S\$
TTO A	
US\$ US	
Income	
Net gains on financial instruments at fair value through	
profit or loss 2,3 1,652,550 98,689,74	10
Net gains on foreign currency movements 7,422 213,16	57
Dividend income 2 1,014,592 3,885,79	15
Interest and other income 454,030 200,02	26
Reclaimed VAT 41,936 46,05	58
<b>Total investment income</b> 3,170,530 103,034,78	36
Expenses	
Investment management fee 6 986,139 3,317,33	34
Administration fee 6 130,536 235,94	12
Global registration fees 65,080 178,48	38
Depositary fee 6 41,319 84,53	<i>5</i> 7
Legal fee 41,601 72,98	36
Transfer agent fees 13,745 37,06	5
Directors' fees 8 55,085 72,83	31
Audit fee 6 22,560 27,99	19
Other expenses 7 154,012 192,79	8
<b>Total expenses</b> 1,510,077 4,219,98	30
Finance Costs	
Withholding tax expense 4 (291,450) (1,047,69	1)
Increase in net assets attributable to holders of	
participating shares 1,369,003 97,767,1	15

# STATEMENT OF CHANGES IN NET ASSETS ATTRIBUTABLE TO HOLDERS OF PARTICIPATING SHARES

For the financial year ended 31 December 2020

	Note	Iridian U.S. Equity Fund 1-Jan-2020 to 31-Dec-2020 US\$	Iridian U.S. Equity Fund 1-Jan-2019 to 31-Dec-2019 US\$
Net assets attributable to holders of participating shares at the beginning of the financial year		213,945,504	448,743,181
Capital Transactions Proceeds from participating shares issued		42,248,532	78,088,397
Cost of participating shares redeemed		(145,129,505)	(410,653,189)
Increase in net assets attributable to holders of participating shares		1,369,003	97,767,115
Net assets attributable to holders of participating shares at the end of the financial year	5	112,433,534	213,945,504

### STATEMENT OF CASH FLOWS For the financial year ended 31 December 2020

	Iridian U.S. Equity Fund 1-Jan-2020 to 31-Dec-2020 US\$	Iridian U.S. Equity Fund 1-Jan-2019 to 31-Dec-2019 US\$
Cash flows from operating activities:		
Increase in net assets resulting from operations	1,369,003	97,767,115
Operating profit before working capital charges	1,369,003	97,767,115
Net decrease in financial assets and financial liabilities at fair value through profit or loss	98,492,092	231,421,421
Net decrease in securities sold receivable	-	3,366,096
Net (increase)/decrease in receivables and prepaid fees	(5,829)	214,031
Net (decrease)/increase in securities purchased payable	(44,164)	214,502
Net decrease in fees payable and accrued expenses	(177,182)	(268,261)
Cash from operations	98,264,917	234,947,789
Net cash from operating activities	99,633,920	332,714,904
Cash flows from financing activities:		
Proceeds from issue of participating shares	41,912,608	86,923,681
Payments for redemptions of participating shares	(144,908,118)	(418,449,779)
Net cash used in financing activities	(102,995,510)	(331,526,098)
Net (decrease)/increase in cash and cash equivalents	(3,361,590)	1,188,806
Cash and cash equivalents at start of the financial year	6,556,333	5,367,527
Cash and cash equivalents at end of the financial year	3,194,743	6,556,333

### 1. Organisation

Iridian UCITS Fund plc (the "Company") was incorporated on 4 November 2013 and is an investment company established as an open-ended umbrella fund with variable capital and segregated liability between its sub-funds under the laws of Ireland as a public limited company pursuant to the Companies Act 2014, the European Communities (Undertakings for Collective Investment in Transferable Securities) Regulations, 2011 (as amended) (the "UCITS Regulations") and the Central Bank (Supervision and enforcement) Act 2013 (Section 48(1)) (Undertakings for Collective Investment in Transferable Securities) Regulations, 2019, as amended (the "Central Bank UCITS Regulations"). The Company has been authorised by the Central Bank of Ireland (the "Central Bank") as an Undertaking for Collective Investment in Transferable Securities ("UCITS"). Notwithstanding the segregation of assets and liabilities between the sub-funds, the Company is a single legal entity and no sub-fund constitutes a legal entity separate from the Company itself.

The Company currently has one active sub-fund, Iridian U.S. Equity Fund (the "Sub-Fund"). The Iridian U.S. Equity Fund was launched on 19 December 2013.

During the financial year ended 31 December 2020, the Sub-Fund remained registered for distribution only in the United Kingdom and Switzerland. The Sub- Fund was registered for distribution in the United Kingdom on 21 March 2014 and in Switzerland on 16 April 2014.

On 29 October 2019, the Sub-Fund was deregistered in Austria, Denmark, Finland, France, Germany, Italy, Norway, Sweden and Singapore. On 21 February 2020, the Sub-Fund was deregistered in Spain. On 31 December 2020, the Sub-Fund was de-registered in Switzerland. Concurrent with deregistration in these jurisdictions, respective paying agents, transfer agents and tax representatives were deregistered as well.

Additional sub-funds may be added to the Company by the Directors from time to time with the prior approval from the Central Bank, each with a separate investment objective and policies. The Company may issue shares of more than one class in each sub-fund.

The Company has appointed Iridian Asset Management LLC (the "Investment Manager") as the Investment Manager.

The investment objective of the Sub-Fund is to provide long-term capital appreciation. The Sub-Fund will seek to achieve its objective by investing primarily in U.S. publicly traded equity securities. The Sub-Fund may also invest a portion of its assets in equity securities of non-U.S. issuers located primarily in the various developed countries of Europe and Asia. The Sub-Fund will typically hold 40 to 60 securities.

### 2. Basis of Preparation and Significant Accounting Policies

#### **Statement of Compliance**

The Company's financial statements have been prepared in accordance with International Financial Reporting Standards, as adopted by the European Union ("IFRS").

The significant accounting policies adopted by the Company are as follows:

### (a) Basis of Preparation

The financial statements have been prepared under the historical cost convention as modified by the revaluation of financial assets and financial liabilities held at fair value through profit or loss.

The financial statements have been prepared on a going concern basis, which is an appropriate basis of preparation based on the financial position of the Company as at 31 December 2020. The Board of Directors has not identified any material uncertainties related to events or conditions that may cast significant doubt about the ability of the Company to continue as a going concern.

### 2. Basis of Preparation and Significant Accounting Policies – (continued)

### (b) Use of Estimates and Judgements

The preparation of financial statements in conformity with IFRS, requires management to make estimates and assumptions that affect the amounts of assets and liabilities reported in the financial statements and disclosure of contingent assets and liabilities in the accompanying notes. Actual results could differ from those estimates. Management believes that the estimates utilised in preparing its financial statements are reasonable and prudent.

The financial statements are prepared in U.S. Dollars ("US\$"), the functional currency of the Company.

### (c) Standards and amendments to existing standards effective 1 January 2020

There are no standards, amendments to standards or interpretations that are effective for annual periods beginning on 1 January 2020 that have a material effect on the financial statements of the Company.

# (d) New Standards, Amendments and Interpretations issued but not effective for the financial year beginning 1 January 2020 and not early adopted

There are no standards, amendments or interpretations that are not yet effective and that would be expected to have a significant impact on the Company.

### (e) Financial Assets and Financial Liabilities at Fair Value Through Profit or Loss

### (i) Classification

A financial asset or liability is classified as being measured at: amortised cost, fair value through other comprehensive income or fair value through profit or loss. The classification of a financial asset or liability is based on the business model in which the financial asset or liability is managed and on its contractual cash flow characteristics.

Investments in equity instruments are managed and performance is evaluated on a fair value basis. The Company is primarily focused on fair value information and uses that information to assess the assets' performance and make decisions. As a result, equity instruments are measured at fair value through profit or loss. Derivative position continue to be held at fair value upon application of IFRS 9 Financial Instruments ("IFRS 9").

All other financial assets and liabilities including cash, cash equivalents, receivables and payables are classified as being measured at amortised cost. Measurement at amortised cost takes into account any premium or discount on acquisition as well as transaction costs and fees that are an integral part of the effective interest rate. All financial assets measured at amortised cost are short term in nature and the application of the expected credit loss model does not impact the carrying amounts of these financial assets as they approximate their fair values under IFRS 9.

### (ii) Recognition/derecognition

Regular-way purchases and sales of investments are recognised on trade date - the date on which the Sub-Fund commits to purchase or sell the asset. Investments are derecognised when the rights to receive cash flows from the investments have expired or the Sub-Fund has transferred substantially all risks and rewards of ownership.

### 2. Basis of Preparation and Significant Accounting Policies – (continued)

### (e) Financial Assets and Financial Liabilities at Fair Value Through Profit or Loss (continued)

### (iii) Measurement

Investments are initially recognised at fair value. Transaction costs for all financial assets and financial liabilities carried at fair value through profit or loss are expensed in the Statement of Comprehensive Income as part of net gains/(losses) on financial instruments at fair value through profit or loss as incurred.

After initial measurement, the Company measures financial instruments which are classified as at fair value through profit or loss, at their fair values. The fair value of financial instruments is based on their quoted market prices on a recognised exchange or, in the case of non-exchange traded instruments, sourced from a reputable broker/counterparty at the Statement of Financial Position date without any deduction for estimated future selling costs. Financial assets and liabilities are priced at their last traded price.

The fair value of investments traded on a market is based on their last traded price on the date of determination, on the market where such instruments are principally traded. Where such investment is quoted, listed or traded on or under the rules of more than one market, the Directors shall in their absolute discretion, select the market, which in their opinion, constitutes the main market for such investment for the foregoing purposes.

### (iv) Forward Foreign Currency Contracts

A forward contract is an agreement between two parties to buy or sell a currency at a set price on a future date. The market value of a forward foreign currency contract fluctuates with changes in forward currency exchange rates. Forward foreign currency contracts are marked-to-market and the change in value is recorded by the Sub-Fund as an unrealised gain or loss. Realised gains or losses equal to the difference between the value of the contract at the time it was opened and the value at the time it was closed are recorded upon delivery or receipt of the currency or, if a forward currency contract is offset by entering into another forward currency contract with the same broker, upon settlement of the net gain or loss. Realised and unrealised gains or losses are accounted for in the Statement of Comprehensive Income. Forward foreign currency contracts are used for hedging purposes.

### (f) Cash and Cash Equivalents

Cash comprises cash on hand. Cash equivalents are short term, highly liquid investments with original maturities of three months or less and bank overdrafts.

With effect 1 April 2016, the Central Bank introduced the Investor Money Regulations which introduces new regulations and compliance requirements surrounding client assets. The Administrator reviewed the way in which funds arising out of subscriptions and redemptions were being channelled into and out of the Company and, arising out of this review, established a separate bank account to administer this process accordingly.

Cash held in investor money collection accounts represents cash balances maintained in an independent cash account in the name of the Company, which relate to pending issuance of shares or payments of redemptions. These cash balances are regarded as assets of the Company and are therefore recognised on the Statement of Financial Position under cash and cash equivalents. As at 31 December 2020, the balances in these accounts were US\$402 and GBP£372,224 (31 December 2019: US\$25 and GBP£60,613).

### (g) Income Recognition

Investment income is reported gross of withholding tax. Dividends are recognised as income on the dates the securities are first quoted "ex dividend" to the extent that information thereon is reasonably available to the Company. Fixed interest, bank deposit interest and other income are accounted for on an effective interest basis.

### 2. Basis of Preparation and Significant Accounting Policies – (continued)

### (h) Finance Costs

Distributions to holders of redeemable shares are recognised in the Statement of Comprehensive Income as finance costs in the financial year in which the dividend is declared.

#### (i) Foreign Currency

The Company's functional currency for all operations is the U.S. Dollar ("US\$"). Non-monetary foreign assets and liabilities are translated at historical rates and monetary foreign assets and liabilities are translated at exchange rates in effect at the end of the financial year.

Transactions during the financial year, including purchases and sales of securities, income and expenses, are translated at the rate of exchange prevailing on the date of the transaction.

The Company does not isolate that portion of the results of operations resulting from the changes in foreign exchange rates on investments from the fluctuations arising from changes in market prices of investments held. Such fluctuations are included with the net realised gains and losses from investments.

### (i) Gains and Losses on Investments

Realised gains and losses on sales of investments are calculated based on a first-in, first-out basis. The associated foreign exchange movement between the date of purchase and the date of sale on the sale of investments is included in net gains/(losses) on financial instruments at fair value through profit or loss in the Statement of Comprehensive Income.

Movement in unrealised gains and losses on investments arising during the financial year are also included in net gains/(losses) on financial instruments at fair value through profit and loss in the Statement of Comprehensive Income.

### (k) Participating Shares

All participating shares issued by the Company provide the investors with the right to require redemption for cash at the value proportionate to the investor's share in the Company's net assets at the redemption date. The participating shares which comprise the capital of the Company are in substance a liability of the Sub-Fund to shareholders under IAS 32 "Financial Instruments: Presentation".

In accordance with the Prospectus, the Company is contractually obliged to redeem shares at the net asset value per share, less any applicable charge.

### (l) Expenses

All expenses, including investment management fees are recognised in the Statement of Comprehensive Income on an accruals basis.

### (m) Offsetting Financial Instruments

As at 31 December 2020 and 31 December 2019, the Sub-Fund holds no derivative instruments or other financial instruments that are eligible for offsetting in the Statement of Financial Position, apart from the Forward Foreign Currency Contacts that are used by the Sub-Fund for hedging purposes.

### (n) Transaction Costs

Transaction costs include all incremental costs that are directly attributable to the acquisition, issue or disposal of a financial asset or financial liability. All transaction costs are recognised in the Statement of Comprehensive Income and are included in net gains/(losses) on financial instruments at fair value through profit or loss.

### 3. Net gains on financial instruments at fair value through profit or loss

Iridian U.S. Equity Fund	1 January 2020	1 January 2019
	- 31 December 2020 - 3	31 December 2019
	US\$	US\$
Net realised gains/(losses) on financial instruments at fair		
value through profit or loss	1,446,467	(18,825,277)
Net movement in unrealised gains on financial		
instruments at fair value through profit or loss	206,083	117,515,017
	1,652,550	98,689,740

#### 4. Taxation

Under current law and practice, the Company qualifies as an investment undertaking as defined in Section 739B of the Taxes Consolidation Act, 1997, as amended. On that basis, it is not chargeable to Irish tax on its income or gains.

However, Irish tax may arise on the happening of a "chargeable event". A chargeable event includes any distribution payments to shareholders, any encashment, redemption, cancellation or transfer of shares and the holding of shares at the end of each eight year period beginning with the acquisition of such shares.

No Irish tax will arise on the Company in respect of chargeable events in respect of:

- (a) a shareholder who is neither Irish resident nor ordinarily resident in Ireland for tax purposes, at the time of the chargeable event, provided appropriate valid declarations in accordance with the provisions of the Taxes Consolidation Act, 1997, as amended, are held by the Company or the Company has been authorised by the Irish Revenue to make gross payments in the absence of appropriate declarations; and
- (b) certain exempted Irish tax resident shareholders who have provided the Company with the necessary signed statutory declarations.

The Finance Act 2010 provides that the Revenue Commissioners may grant approval for investment funds marketed outside of Ireland to make payments to non-resident investors without deduction of Irish tax where no relevant declaration is in place, subject to meeting the "equivalent measures". A fund wishing to receive approval must apply in writing to the Revenue Commissioners, confirming compliance with the relevant conditions.

Dividends, interest and capital gains (if any) received on investments made by the Company may be subject to taxes imposed by the country from which the investment income/gains are received and such taxes may not be recoverable by the Company or its shareholders.

### 5. Share Capital

### Authorised

The authorised share capital of the Company is 300,000 redeemable non-participating shares of no par value and 500,000,000,000 participating shares of no par value.

### Non-participating shares

There are two non-participating shares currently in issue, held by an individual nominee in trust for the Investment Manager. The subscriber shares do not form part of the net asset value of the Company and are thus disclosed in the financial statements by way of this note only. In the opinion of the Directors, this disclosure reflects the nature of the Company's business as an investment company.

### 5. Share Capital – (continued)

### Participating shares

The issued participating share capital is at all times equal to the net asset value of the Company. The movements in the number of participating shares for the financial year ended 31 December 2020 and 31 December 2019; and Net Asset Value and Net Asset Value per share figures as at 31 December 2020, 31 December 2019 and 31 December 2018 are disclosed on the following pages.

Iridian U.S. Equity Fund			
1 January 2020 - 31 December 2020	Class I USD (A)	Class IP USD (A)	Class I USD (D)
Opening Balance	30,456	935,719	50,221
Partcipating shares issued	-	22,365	120
Partcipating shares redeemed	(15,831)	(650,507)	(34,507)
Closing Balance	14,625	307,577	15,834
1 January 2020 - 31 December 2020	Class I GBP (A)	Class I GBP (D)	Class Y USD (A)
Opening Balance	72,951	14,329	25,999
Partcipating shares issued	14,825	1	-
Partcipating shares redeemed	(17,582)	(14,330)	(25,999)
Closing Balance	70,194	-	<u> </u>
1 January 2020 - 31 December 2020	Class Z USD (A)	Class IP EUR (D)	Class IP GBP (D)
Opening Balance	37,797	918	386,472
Partcipating shares issued	-	35	18,714
Partcipating shares redeemed	(23,311)	(953)	(391,946)
Closing Balance	14,486	-	13,240
1 January 2020 - 31 December 2020 Opening Balance	Class A GBP (D)		
Partcipating shares issued	269,232		
Partcipating shares redeemed	(23,447)		
Closing Balance	245,785		
(H) - Hedged			
Iridian U.S Equity Fund			
31 December 2020	Class I USD (A)	Class IP USD (A)	Class I USD (D)
Net Asset Value <sup>1</sup>	2,374,739	48,700,145	2,290,934
Participating share in issue	14,625	307,577	15,834

<sup>&</sup>lt;sup>1</sup>The Net Asset Value is shown in the base currency of the Fund (US\$).

Net Asset Value per share <sup>2</sup>

162.36

158.33

144.68

<sup>&</sup>lt;sup>2</sup>The Net Asset Value per Share is shown in the local currency.

### 5. Share Capital – (continued)

Iridian U.S Equity Fund (continued)			
31 December 2020	Class I GBP (A)	Class Z USD (A)	Class IP GBP (D)
Net Asset Value <sup>1</sup>	15,682,826	2,049,361	2,281,205
Participating share in issue	70,194	14,486	13,240
Net Asset Value per share <sup>2</sup>	163.38	141.48	125.99
•			
31 December 2020	Class A GBP (D)		
Net Asset Value <sup>1</sup>	39,054,324		
Participating share in issue	245,785		
Net Asset Value per share <sup>2</sup>	116.19		
Iridian U.S. Equity Fund			
1 January 2019 - 31 December 2019	Class I USD (A)	Class IP USD (A)	Class I USD (D)
Opening Balance	291,999	541,078	258,064
Partcipating shares issued	1,294	468,486	6,796
Partcipating shares redeemed	(262,837)	(73,845)	(214,639)
Closing Balance	30,456	935,719	50,221
1 January 2019 - 31 December 2019	Class I GBP (A)	Class I GBP (D)	Class Y USD (D)
Opening Balance	437,441	55,961	2,138
Participating shares issued	16,685	2,018	(2.129)
Partcipating shares redeemed Closing Balance	(381,175) 72,951	(43,650) 14,329	(2,138)
Closing Balance	12,931	14,329	<del>-</del>
1 January 2019 - 31 December 2019	Class Y USD (A)	Class Y EUR (A)(H)	Class Z USD (A)
Opening Balance	114,456	7,940	159,944
Partcipating shares issued	9,059	-	2,527
Partcipating shares redeemed	(97,516)	(7,940)	(124,674)
Closing Balance	25,999	-	37,797
1 January 2019 - 31 December 2019	Class IP EUR (D)	Class IP GBP (D)	
Opening Balance	3,478	2,207,124	
Partcipating shares issued	453	129,277	
Partcipating shares redeemed	(3,013)		
Closing Balance	918	386,472	
(H) - Hedged		,	•
THE MORE WE			
Iridian U.S Equity Fund	Classifica (A)	Class ID LICE (A)	Class LUCD (D)
31 December 2019	Class I USD (A)	Class IP USD (A)	Class I USD (D)
Net Asset Value <sup>1</sup>	4,146,212	123,907,613	6,093,402
Participating share in issue Net Asset Value per share <sup>2</sup>	30,456 136.14	935,719 132.42	50,221 121.33
<sup>1</sup> The Net Asset Value is shown in the base currency		132.42	121.55
<sup>2</sup> The Net Asset Value per Share is shown in the local			

<sup>24</sup> 

#### 5. Share Capital – (continued)

Iridian U.S Equity Fund (continued)			
31 December 2019	Class I GBP (A)	Class I GBP (D)	Class Y USD (A)
Net Asset Value <sup>1</sup>	13,666,389	2,646,340	3,157,102
Participating share in issue	72,951	14,329	25,999
Net Asset Value per share <sup>2</sup>	141.43	140.86	121.43
31 December 2019	Class Z USD (A)	Class IP EUR (D)	Class IP GBP (D)
Net Asset Value <sup>1</sup>	4,481,153	107,781	55,739,512
Participating share in issue	37,797	918	386,472
Net Asset Value per share <sup>2</sup>	118.56	104.67	108.83
Iridian U.S Equity Fund			
31 December 2018	Class I USD (A)	Class IP USD (A)	Class I USD (D)
Net Asset Value <sup>1</sup>	30,403,804	54,656,373	23,945,875
Participating share in issue	291,999	541,078	258,064
Net Asset Value per share <sup>2</sup>	104.12	101.01	92.79
31 December 2018	Class I GBP (A)	Class I GBP (D)	Class Y USD (D)
Net Asset Value <sup>1</sup>	62,675,168	7,985,508	197,362
Participating share in issue	437,441	55,961	2,138
Net Asset Value per share <sup>2</sup>	112.41	111.95	92.30
31 December 2018	Class Y USD (A)	Class Y EUR (A)(H)	Class Z USD (A)
Net Asset Value <sup>1</sup>	10,560,961	781,975	14,505,212
Participating share in issue	114,456	7,940	159,944
Net Asset Value per share <sup>2</sup>	92.27	85.96	90.69
31 December 2018	Class IP EUR (D)	Class IP GBP (D)	
Net Asset Value <sup>1</sup>	311,541	242,719,402	
Participating share in issue	3,478	2,207,124	
Net Asset Value per share <sup>2</sup>	78.17	86.28	

<sup>&</sup>lt;sup>1</sup>The Net Asset Value is shown in the base currency of the Fund (US\$). <sup>2</sup>The Net Asset Value per Share is shown in the local currency.

### 5. Share Capital – (continued)

The relevant movements in share capital are shown in the Statement of Changes in Net Assets Attributable to Holders of Participating Shares. The Company invests the proceeds from the issue of shares in investments while maintaining sufficient liquidity to meet redemptions when necessary.

### 6. Fees and Expenses

### Investment Management Fee

Iridian Asset Management LLC is entitled to receive out of the net assets of the Sub-Fund an investment management fee calculated as a percentage of the Net Asset Value of the Sub-Fund, accrued and calculated at each valuation point and payable monthly in arrears as follows:

### Iridian U.S. Equity Fund

Class I USD (A)	1.25% p/a
Class IP USD (A)	1.00%  p/a
Class IP EUR (D)	1.00%  p/a
Class IP GBP (D)	1.00%  p/a
Class I USD (D)	1.25% p/a
Class I GBP (A)	1.25%  p/a
Class I GBP (D)	1.25% p/a
Class R USD (A)	1.75%  p/a
Class Y USD (D)	Up to 1% p/a*
Class Y USD (A)	Up to 1% p/a*
Class Y EUR (A)(H)	Up to 1% p/a*
Class Z USD (D)	Up to 1.5% p/a*
Class Z USD (A)	Up to 1.5% p/a*
Class Z EUR (A)(H)	Up to 1.5% p/a*
Class A GBP (D)	Up to 0.95% p/a*
*This maximum figure represents the total expense ratio for the Class	The actual Investment Management Fee t

<sup>\*</sup>This maximum figure represents the total expense ratio for the Class. The actual Investment Management Fee payable will fluctuate based upon the operational fee of each Class.

During the financial year ended 31 December 2020, the Investment Manager earned investment management fees of US\$986,139 (2019: US\$3,317,334) and at 31 December 2020 US\$84,804 (31 December 2019: US\$192,651) remained payable to the Investment Manager.

#### Performance Fee

The Investment Manager is also entitled to receive out of the net assets of the Sub-Fund a performance fee calculated as a percentage of the aggregate appreciation in value of the relevant Class performance in excess of the Russell 1000 Index (the "Hurdle Rate"), accrued and calculated daily and paid annually on the rate of return of each Class and will be payable annually in arrears or upon repurchase, if earlier, as follows:

#### Iridian U.S. Equity Fund

man eist Equity I and	
Class I USD (A)	Nil
Class IP USD (A)	Nil
Class IP EUR (D)	Nil
Class IP GBP (D)	Nil
Class I USD (D)	Nil
Class I GBP (A)	Nil
Class I GBP (D)	Nil
Class R USD (A)	Nil
Class Y USD (D)	10% p/a per Class
Class Y USD (A)	10% p/a per Class
Class Y EUR (A)(H)	10% p/a per Class
Class Z USD (D)	10% p/a per Class
Class Z USD (A)	10% p/a per Class
Class Z EUR (A)(H)	10% p/a per Class
Class A GBP (D)	Nil

### 6. Fees and Expenses – (continued)

#### Performance Fee (continued)

During the financial year ended 31 December 2020, the Investment Manager earned performance fees of US\$Nil (2019: US\$Nil) and at 31 December 2020 US\$Nil (31 December 2019: US\$Nil) remained payable to the Investment Manager.

### Administration fee

SEI Investments - Global Fund Services Limited, (the "Administrator"), is entitled to receive out of the net assets of the Sub-Fund an annual fee up to a maximum of 0.05% of the Net Asset Value of the Sub-Fund, accrued and calculated monthly and payable monthly in arrears, subject to an annual minimum fee of US\$85,000.

During the financial year ended 31 December 2020, the Administrator earned administration fees of US\$130,536 (2019: US\$235,942) and at 31 December 2020 US\$28,164 (31 December 2019: US\$47,863) remained payable to the Administrator.

### Depositary fee

SEI Investments - Depositary and Custodial Services (Ireland) Limited, (the "Depositary"), is entitled to receive out of the net assets of the Sub-Fund an annual depositary fee up to a maximum of 0.02% of the Net Asset Value of the Sub-Fund, calculated monthly and payable monthly in arrears.

During the financial year ended 31 December 2020, the Depositary earned fees of US\$41,319 (2019: US\$84,537) and at 31 December 2020 US\$3,178 (31 December 2019: US\$5,196) remained payable to the Depositary.

### Transaction fee

The Company incurred transaction fees throughout the financial year. Transaction costs include all incremental costs that are directly attributable to the acquisition, issue or disposal of a financial asset or financial liability. All transaction costs are recognised in the Statement of Comprehensive Income and are included in net gains/(losses) on financial instruments at fair value through profit or loss.

During the financial year ended 31 December 2020, the Sub-Fund incurred transaction fees of US\$144,766 (2019: US\$475,109).

### Auditors' Remuneration

	•	1 January 2019 - 31 December 2019
	US\$	US\$
Fees in respect of audit of Company financial statements	18,341	22,763
Fees in respect of audit of other assurance services	-	=
Fees in respect of tax advisory services	9,588	19,211
Fees in respect of non-audit services		
	27,929	41,974

The amounts in the above table are exclusive of VAT. The amounts shown in the Statement of Comprehensive Income are inclusive of VAT.

### 7. Other Expenses

Iridian U.S. Equity Fund	1 January 2020	1 January 2019
	- 31 December 2020	- 31 December 2019
	US\$	US\$
Central Bank fees	7,231	4,700
Corporate Secretary fees	31,645	29,675
Directors' Insurance fees	16,335	16,703
Miscellaneous expenses	4,683	14,611
MLRO fees	4,483	5,837
Professional fees	69,422	90,501
Bank fees	20,213	30,771
	154,012	192,798

### 8. Directors' Remuneration

For the financial year ended 31 December 2020 the total Directors' remuneration was US\$55,085 (2019: US\$72,831). Jeffrey M. Elliott and Lane S. Bucklan are affiliated with the Investment Manager and have waived their right to receive compensation from the Company.

### 9. Soft Commission Arrangements

During the reported financial year the Investment Manager has entered into soft commission arrangements with brokers in respect of which certain goods and services were provided by third party vendors who were used to support the investment decision process. The Investment Manager does not make direct payment to these third party vendors but does transact business with the brokers on behalf of the Company and commission is paid on these transactions, a portion of which is directed to pay the third party vendor. The Investment Manager used soft commissions generated from trades with the below brokers to pay for goods and services provided by third party vendors:

1 January 2020	1 January 2019
- 31 December 2020 - 3	31 December 2019
US\$	US\$
646	1,887
25,618	57,449
13	=
1,794	250
922	16,655
47,017	99,422
76,010	175,663
	- 31 December 2020 - 3 US\$ 646 25,618 13 1,794 922 47,017

### 10. Related Party Disclosure and Connected Persons Transactions

The Investment Manager has earned Investment Management fees, the specific details of which are contained in Note 6.

SEI Investments - Global Fund Services Limited acts as Administrator and Transfer Agent to the Company.

SEI Investments - Depositary and Custodial Services (Ireland) Limited acts as Depositary to the Company.

Details of the fees earned by the Administrator and Depositary to the Company are contained in Note 6.

### 10. Related Party Disclosure and Connected Persons Transactions (continued)

The Director Jeffrey M. Elliott is the Executive Vice President, Chief Operating Officer and Chief Financial Officer of Iridian Asset Management LLC, the Investment Manager of the Company as at 31 December 2020. The Director Lane S. Bucklan is the Chief Administrative Officer, General Counsel and Chief Compliance Officer of Iridian Asset Management LLC, the Investment Manager of the Company as at 31 December 2020. In the case of Director Gerald Brady, the Company has, as of the date of this report, engaged an entity related to Mr. Brady to provide director support services to the Company. Directors' fees (incorporating director support services fees in the case of Mr. Brady) are disclosed in Note 8.

Shareholders should be aware that not all "connected persons" as defined by the Central Bank UCITS Regulations are "related parties" as defined by IAS 24, "Related Party Disclosures". Details of fees paid to related parties and certain connected persons are set out in Note 6, 7 and 10.

#### 11. Distributions

The Directors did not declare any dividends for the financial year ended 31 December 2020 or 31 December 2019.

#### 12. Risks associated with financial instruments

The Sub-Fund has exposure to the following specific risks from financial instruments:

- market risk (including price risk, currency risk and interest rate risk);
- liquidity risk; and
- credit risk.

### (a) Market Risk

Market risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market variables such as investment prices, foreign exchange rates and interest rates. The likelihood of these types of adverse changes and the extent to which they affect the business of the Sub-Fund cannot always be accurately predicted.

### (i) Price Risk

Price risk is the risk that the value of an investment may fluctuate as a result of changes in market prices, whether caused by factors specific to an individual investment or all factors affecting all instruments traded in the market.

The Investment Manager attempts to mitigate this risk by maintaining a diverse portfolio. As of 31 December 2020 the Sub-Fund had 47 positions (2019: 46 positions) with the top five less than 20% of net assets (31 December 2019: 19%).

The Sub-Fund also attempts to mitigate risk by diversifying its investments across multiple industries. As of 31 December 2020, the Sub-Fund was invested in 27 industries (2019: 25 industries) with the highest industry exposure being 25% of net assets (2019: 35%).

If the price of the equity investment in the Sub-Fund's portfolio as at 31 December 2020 increased by 10%, this would have resulted in an increase of US\$10.97 million in the net assets of the Sub-Fund (2019: US\$20.82 million). A decrease would have resulted in an equal but opposite movement. 10% is deemed a reasonable estimate of the price movements in the portfolio.

### 12. Risks associated with financial instruments (continued)

### (a) Market Risk (continued)

### (ii) Currency Risk

Currency risk is the risk that the value of a financial instrument will fluctuate due to changes in foreign exchange rates. As at 31 December 2020 and 31 December 2019, the Sub-Fund does not hold any securities or other investments denominated in currencies other than the functional currency of the Company.

The Sub-Fund held foreign cash balances that represent a small fraction of the total assets of the Company. While these foreign cash balances are subject to currency rate risk, the risk for the Sub-Fund is immaterial.

Foreign currency rates used in the preparation of these financial statements are disclosed in Note 14.

### (iii) Interest Rate Risk

As at 31 December 2020 and 31 December 2019, the Company has little exposure to interest rate risk. The Company has no exposure to interest rate sensitive instruments such as fixed income securities. The cash balances held, while subject to interest rate risk, are a small fraction of the total assets of the Company.

### (b) Liquidity Risk

This is the risk that a lack of a market in certain portfolio securities could prevent the Sub-Fund from liquidating unfavourable positions or prevent the Sub-Fund from funding redemption requests from existing shareholders or meeting other obligations associated with its liabilities. As at 31 December 2020 and 31 December 2019, the Sub-Fund's investments are all readily realisable (within one month).

The following tables detail the Sub-Fund's remaining contractual maturity for its financial liabilities.

Iridian U.S. Equity Fund	Less than	1 month to	3 months to	Total
31 December 2020	1 month	3 months	12 months	
	US\$	US\$	US\$	US\$
Liabilities				
Financial liabilities at fair value				
through profit or loss	1,680	-	-	1,680
Securities purchased payable	170,338	-	-	170,338
Redemptions payable	509,419	-	-	509,419
Investment management fee payable	84,804	-	-	84,804
Administration fee payable	-	28,164	-	28,164
Audit fee payable	28,000	-	-	28,000
Legal fee payable	5,000	-	-	5,000
Depositary fee payable	3,178	-	-	3,178
Other accrued expenses	20,205	-	-	20,205
Redeemable participating shares				
(based on dealing NAV)	112,433,534	-	-	112,433,534
Total Liabilities	113,256,158	28,164	-	113,284,322

### 12. Risks associated with financial instruments (continued)

### (b) Liquidity Risk (continued)

Iridian U.S. Equity Fund 31 December 2019	Less than 1 month	1 month to 3 months	3 months to 12 months	Total
T . 1 . 1	US\$	US\$	US\$	US\$
Liabilities				
Financial liabilities at fair value				
through profit or loss	1,291	-	-	1,291
Securities purchased payable	214,502	-	-	214,502
Redemptions payable	288,032	=	-	288,032
Investment management fee payable	192,651	=	-	192,651
Administration fee payable	-	47,863	-	47,863
Audit fee payable	30,083	=	=	30,083
Legal fee payable	7,268	=	=	7,268
Depositary fee payable	5,196	-	-	5,196
Other accrued expenses	63,472	-	-	63,472
Redeemable participating shares				
(based on dealing NAV)	213,945,504	-	=	213,945,504
Total Liabilities	214,747,999	47,863	-	214,795,862

#### (c) Credit Risk

The Sub-Fund currently holds its assets and its cash and cash equivalents with Brown Brothers Harriman (the "Sub-Custodian"). The Sub-Custodian credit rating as at 31 December 2020 from Fitch was A+ (2019: Fitch A+). Insolvency or bankruptcy of the Depositary or the Sub-Custodian may cause the Company's rights with respect to its assets held by the Depositary or the Sub-Custodian to be delayed or limited. There has been no change in the rating of the Sub-Custodian since 31 December 2020.

### 13. Fair Value Measurement

For fair value measurements recognised in the Statement of Financial Position, IFRS 13, 'Fair Value Measurement' ("IFRS 13") requires certain fair value disclosures for each class of financial instruments. For this purpose, IFRS 13 requires an entity to classify fair value measurements into a fair value hierarchy, with the following levels, by reference to the observability and significance of the inputs used in making the measurements.

For a fair value measurement of a financial instrument to be classified in Level 1 of the hierarchy, it should be observable directly in an active market for the same instrument.

Fair value measurement in Levels 2 and 3 of the hierarchy are determined using valuation techniques. The level in the hierarchy into which a financial instrument's fair value measurement is classified in its entirety and is determined by reference to the observability and significance of the inputs used in the valuation model. Valuation techniques often incorporate both observable inputs and unobservable inputs.

Fair value measurements determined using valuation techniques are classified in their entirety in either Level 2 or 3 based on the lowest level input that is significant to the measurement. That is, if the model uses both observable and unobservable inputs, the fair value measurement is classified in Level 3 if the unobservable inputs are significant to their fair value measurement in its entirety. This assessment is made independently of the number or the quality of the Level 2 inputs used in the model.

Differentiating between Level 2 and Level 3 fair value measurements, i.e., assessing whether inputs are observable and whether the unobservable inputs are significant, may require judgement and a careful analysis of the inputs used to measure fair value, including consideration of factors specific to the asset or liability.

### 13. Fair Value Measurement (continued)

The following tables provide an analysis within the fair value hierarchy of the Company's financial assets and liabilities, measured at fair value at 31 December 2020:

Iridian U.S. Equity Fund	Level 1	Level 2	Level 3	
31 December 2020	<b>Quoted Prices</b>	Significant Other	Significant Other	
	In Active	Observable	Unobservable	
	Markets	Inputs	Inputs	Total
	US\$	US\$	US\$	US\$
Financial Assets at Fair Value				
Through Profit or Loss				
Equities	109,693,047	-	-	109,693,047
Forward Foreign Currency Contracts	-	1,970	-	1,970
Assets not measured at fair value				
Cash and cash equivalents	3,194,743	_	_	3,194,743
Subscriptions receivable	-	376,959	_	376,959
Dividend receivable	_	17,603	_	17,603
Total assets	112,887,790	396,532	-	113,284,322
Financial Liabilities at Fair Value				
Through Profit or Loss				
Forward Foreign Currency Contracts		1,680		1,680
Tot ward Poteign Currency Contracts	-	1,000	-	1,000
Liabilities not measured at fair value	2			
Redemptions payable	-	509,419	-	509,419
Securities purchased payable	-	170,338	-	170,338
Accrued expenses and other payables		169,351	-	169,351
Total liabilities	-	850,788	-	850,788

### 13. Fair Value measurement – (continued)

The following tables provide an analysis within the fair value hierarchy of the Company's financial assets and liabilities, measured at fair value at 31 December 2019:

Iridian U.S. Equity Fund 31 December 2019	Level 1 Quoted Prices In Active	Level 2 Significant Other Observable	Level 3 Significant Other Unobservable	
	Markets US\$	Inputs US\$	Inputs US\$	Total US\$
Financial Assets at Fair Value Through Profit or Loss				0.54
Equities	208,186,400	_	-	208,186,400
Forward Foreign Currency Contracts	-	320	-	320
Assets not measured at fair value Cash and cash equivalents Subscriptions receivable	6,556,333	41,035	<u>-</u>	6,556,333 41,035
Dividend receivable	214742722	11,774	-	11,774
Total assets	214,742,733	53,129	<u>-</u>	214,795,862
Financial Liabilities at Fair Value Through Profit or Loss Forward Foreign Currency Contracts		1,291	_	1,291
Torward Foreign Currency Contracts		1,271		1,271
Liabilities not measured at fair value	2			
Redemptions payable	-	288,032	-	288,032
Securities purchased payable	-	214,502	-	214,502
Accrued expenses and other payables	-	346,533	-	346,533
Total liabilities		850,358	-	850,358

There were no transfers between levels for securities held during the financial year ended 31 December 2020 and 31 December 2019.

Policies regarding fair value measurement are included in Note 2.

### 14. Foreign Exchange Rates

As of 31 December 2020 and 31 December 2019, the following exchange rates were used in the preparation of these financial statements:

	<b>31 December 2020</b>	<b>31 December 2019</b>
USD/EUR	0.8186	0.8915
USD/GBP	0.7313	0.7549

### 15. Events during the reporting financial year

On 21 February 2020, the Sub-Fund, Iridian U.S. Equity Fund was de-registered in Spain. On 31 December 2020, the Sub-Fund, Iridian U.S. Equity Fund was de-registered in Switzerland.

The 2020 global outbreak of the novel coronavirus ("COVID-19"), together with resulting voluntary and governmental actions, including, without limitation, mandatory business closures, public gathering limitations, restrictions on travel and quarantines, has meaningfully disrupted the US and global economy and markets. Although the long-term economic fallout of COVID-19 is difficult to predict, it has had and is expected to continue to have potentially ongoing material adverse effects across various aspects of the regional, national and global economy. To date, the pandemic has not had a materially adverse impact on the Fund's operations. The Directors continue to monitor the impact of the pandemic on the Fund.

There have been no other material events during the financial year ended 31 December 2020 that would require adjustment or disclosure in these financial statements.

### 16. Events after the reporting financial year end

There have been no material events since 31 December 2020 that would require adjustment or disclosure in these financial statements.

### 17. Efficient portfolio management

During the financial year ended 31 December 2020 and 31 December 2019, the Sub-Fund used Forward Foreign Currency Contracts to hedge the currency risk related to share classes issued in a currency different from the base currency of the Sub-Fund. The Forward Foreign Currency Contracts were not therefore used for investment purposes or for efficient portfolio management purposes. These contracts do not constitute a hedging relationship for hedge accounting in accordance with IFRS 9.

During the financial year ended 31 December 2020 and 31 December 2019, the Sub-Fund was not involved in repurchase agreements or securities lending.

### 18. Approval of financial statements

The financial statements were approved and authorised for issue by the Directors on 27 April 2021.

# SCHEDULE OF SIGNIFICANT CHANGES IN THE PORTFOLIO For the financial year ended 31 December 2020

## Iridian U.S. Equity Fund

Top 20 Purchases	US\$
Axsome Therapeutics, Inc.	3,454,511
Restaurant Brands International Inc.	2,526,708
Post Holdings Inc.	2,457,995
Alexion Pharmaceuticals Inc.	2,278,202
Wynn Resorts Ltd	2,177,320
Splunk Inc.	2,013,673
Slack Technologies Inc.	2,007,191
Marriott Vacations Worldwide Corporation	1,805,025
HD Supply Holdings Inc.	1,774,546
Uber Technologies Inc.	1,749,600
Qorvo Inc.	1,738,009
Dell Technologies Inc.	1,734,195
Zynga Inc.	1,679,675
Martin Marietta Materials Inc.	1,674,057
ServiceMaster Global Holdings Inc.	1,619,138
Mylan NV	1,608,310
IAC/InterActiveCorp.	1,596,667
Colony Capital Inc.	1,554,798
Ashland Global Holdings Inc.	1,493,301
Molina Healthcare Inc.	1,456,808
Ton 20 Solos	UCC
Top 20 Sales	US\$
HD Supply Holdings Inc.	8,659,657
HD Supply Holdings Inc. Alexion Pharmaceuticals Inc.	8,659,657 7,490,148
HD Supply Holdings Inc. Alexion Pharmaceuticals Inc. General Mills, Inc.	8,659,657 7,490,148 6,933,143
HD Supply Holdings Inc. Alexion Pharmaceuticals Inc. General Mills, Inc. Marathon Petroleum Corp.	8,659,657 7,490,148 6,933,143 6,181,851
HD Supply Holdings Inc. Alexion Pharmaceuticals Inc. General Mills, Inc. Marathon Petroleum Corp. Laboratory Corp of America Holdings	8,659,657 7,490,148 6,933,143 6,181,851 5,796,292
HD Supply Holdings Inc. Alexion Pharmaceuticals Inc. General Mills, Inc. Marathon Petroleum Corp. Laboratory Corp of America Holdings Tyson Foods Inc.	8,659,657 7,490,148 6,933,143 6,181,851 5,796,292 5,568,121
HD Supply Holdings Inc. Alexion Pharmaceuticals Inc. General Mills, Inc. Marathon Petroleum Corp. Laboratory Corp of America Holdings Tyson Foods Inc. AutoZone Inc.	8,659,657 7,490,148 6,933,143 6,181,851 5,796,292 5,568,121 5,158,150
HD Supply Holdings Inc. Alexion Pharmaceuticals Inc. General Mills, Inc. Marathon Petroleum Corp. Laboratory Corp of America Holdings Tyson Foods Inc. AutoZone Inc. Molina Healthcare Inc.	8,659,657 7,490,148 6,933,143 6,181,851 5,796,292 5,568,121 5,158,150 4,981,028
HD Supply Holdings Inc. Alexion Pharmaceuticals Inc. General Mills, Inc. Marathon Petroleum Corp. Laboratory Corp of America Holdings Tyson Foods Inc. AutoZone Inc. Molina Healthcare Inc. Entegris, Inc.	8,659,657 7,490,148 6,933,143 6,181,851 5,796,292 5,568,121 5,158,150 4,981,028 4,956,782
HD Supply Holdings Inc. Alexion Pharmaceuticals Inc. General Mills, Inc. Marathon Petroleum Corp. Laboratory Corp of America Holdings Tyson Foods Inc. AutoZone Inc. Molina Healthcare Inc. Entegris, Inc. Post Holdings Inc.	8,659,657 7,490,148 6,933,143 6,181,851 5,796,292 5,568,121 5,158,150 4,981,028 4,956,782 4,877,861
HD Supply Holdings Inc. Alexion Pharmaceuticals Inc. General Mills, Inc. Marathon Petroleum Corp. Laboratory Corp of America Holdings Tyson Foods Inc. AutoZone Inc. Molina Healthcare Inc. Entegris, Inc. Post Holdings Inc. Ball Corp.	8,659,657 7,490,148 6,933,143 6,181,851 5,796,292 5,568,121 5,158,150 4,981,028 4,956,782 4,877,861 4,743,131
HD Supply Holdings Inc. Alexion Pharmaceuticals Inc. General Mills, Inc. Marathon Petroleum Corp. Laboratory Corp of America Holdings Tyson Foods Inc. AutoZone Inc. Molina Healthcare Inc. Entegris, Inc. Post Holdings Inc. Ball Corp. Zynga Inc.	8,659,657 7,490,148 6,933,143 6,181,851 5,796,292 5,568,121 5,158,150 4,981,028 4,956,782 4,877,861 4,743,131 4,591,840
HD Supply Holdings Inc. Alexion Pharmaceuticals Inc. General Mills, Inc. Marathon Petroleum Corp. Laboratory Corp of America Holdings Tyson Foods Inc. AutoZone Inc. Molina Healthcare Inc. Entegris, Inc. Post Holdings Inc. Ball Corp. Zynga Inc. Anthem Inc.	8,659,657 7,490,148 6,933,143 6,181,851 5,796,292 5,568,121 5,158,150 4,981,028 4,956,782 4,877,861 4,743,131 4,591,840 4,581,198
HD Supply Holdings Inc. Alexion Pharmaceuticals Inc. General Mills, Inc. Marathon Petroleum Corp. Laboratory Corp of America Holdings Tyson Foods Inc. AutoZone Inc. Molina Healthcare Inc. Entegris, Inc. Post Holdings Inc. Ball Corp. Zynga Inc. Anthem Inc. Flex Ltd.	8,659,657 7,490,148 6,933,143 6,181,851 5,796,292 5,568,121 5,158,150 4,981,028 4,956,782 4,877,861 4,743,131 4,591,840 4,581,198 4,382,453
HD Supply Holdings Inc. Alexion Pharmaceuticals Inc. General Mills, Inc. Marathon Petroleum Corp. Laboratory Corp of America Holdings Tyson Foods Inc. AutoZone Inc. Molina Healthcare Inc. Entegris, Inc. Post Holdings Inc. Ball Corp. Zynga Inc. Anthem Inc.	8,659,657 7,490,148 6,933,143 6,181,851 5,796,292 5,568,121 5,158,150 4,981,028 4,956,782 4,877,861 4,743,131 4,591,840 4,581,198 4,382,453 3,791,150
HD Supply Holdings Inc. Alexion Pharmaceuticals Inc. General Mills, Inc. Marathon Petroleum Corp. Laboratory Corp of America Holdings Tyson Foods Inc. AutoZone Inc. Molina Healthcare Inc. Entegris, Inc. Post Holdings Inc. Ball Corp. Zynga Inc. Anthem Inc. Flex Ltd. Intercontinental Exchange Inc. S&P Global Inc.	8,659,657 7,490,148 6,933,143 6,181,851 5,796,292 5,568,121 5,158,150 4,981,028 4,956,782 4,877,861 4,743,131 4,591,840 4,581,198 4,382,453
HD Supply Holdings Inc. Alexion Pharmaceuticals Inc. General Mills, Inc. Marathon Petroleum Corp. Laboratory Corp of America Holdings Tyson Foods Inc. AutoZone Inc. Molina Healthcare Inc. Entegris, Inc. Post Holdings Inc. Ball Corp. Zynga Inc. Anthem Inc. Flex Ltd. Intercontinental Exchange Inc. S&P Global Inc. ServiceMaster Global Holdings Inc.	8,659,657 7,490,148 6,933,143 6,181,851 5,796,292 5,568,121 5,158,150 4,981,028 4,956,782 4,877,861 4,743,131 4,591,840 4,581,198 4,382,453 3,791,150 3,621,582
HD Supply Holdings Inc. Alexion Pharmaceuticals Inc. General Mills, Inc. Marathon Petroleum Corp. Laboratory Corp of America Holdings Tyson Foods Inc. AutoZone Inc. Molina Healthcare Inc. Entegris, Inc. Post Holdings Inc. Ball Corp. Zynga Inc. Anthem Inc. Flex Ltd. Intercontinental Exchange Inc. S&P Global Inc.	8,659,657 7,490,148 6,933,143 6,181,851 5,796,292 5,568,121 5,158,150 4,981,028 4,956,782 4,877,861 4,743,131 4,591,840 4,581,198 4,382,453 3,791,150 3,621,582 3,563,076
HD Supply Holdings Inc. Alexion Pharmaceuticals Inc. General Mills, Inc. Marathon Petroleum Corp. Laboratory Corp of America Holdings Tyson Foods Inc. AutoZone Inc. Molina Healthcare Inc. Entegris, Inc. Post Holdings Inc. Ball Corp. Zynga Inc. Anthem Inc. Flex Ltd. Intercontinental Exchange Inc. S&P Global Inc. ServiceMaster Global Holdings Inc. L3Harris Technologies, Inc.	8,659,657 7,490,148 6,933,143 6,181,851 5,796,292 5,568,121 5,158,150 4,981,028 4,956,782 4,877,861 4,743,131 4,591,840 4,581,198 4,382,453 3,791,150 3,621,582 3,563,076 3,507,792

### APPENDIX I (UNAUDITED)

# ADDITIONAL INFORMATION FOR INVESTORS IN SWITZERLAND For the financial year ended 31 December 2020

### Total Expense Ratio ("TER")1

The Total Expense Ratio ("TER") was calculated according to currently valid guidelines of the Swiss Funds & Asset Management Association.

The key figures as at 31 December 2020 were as follows:

### TER

Sub-Fund	Share class	TER <sup>1</sup>
Iridian U.S. Equity Fund	Class I USD (A)	1.55%
Iridian U.S. Equity Fund	Class IP USD (A)	1.30%
Iridian U.S. Equity Fund	Class I USD (D)	1.55%
Iridian U.S. Equity Fund	Class I GBP (A)	1.55%
Iridian U.S. Equity Fund	Class IP GBP (D)	1.30%
Iridian U.S. Equity Fund	Class Z USD (A)	1.50%
Iridian U.S. Equity Fund	Class A GBP (D)	0.95%

1) The Total Expense Ratio ("TER" ) is calculated according to the following formula: (total expenses / AF)\* 100  $AF = average \ fund \ assets$ 

Iridian U.S. Equity Fund

Iridian U.S. Equity Fund

### APPENDIX I (UNAUDITED)

# ADDITIONAL INFORMATION FOR INVESTORS IN SWITZERLAND (continued) For the financial year ended 31 December 2020

### Performance

The performance figures as at 31 December 2020 were as follows:

		<b>Year 2020</b>
Sub-Fund	Share class	Performance %
Iridian U.S. Equity Fund	Class I USD (A)	19.26%
Iridian U.S. Equity Fund	Class IP USD (A)	19.57%
Iridian U.S. Equity Fund	Class IP EUR (D)*	-
Iridian U.S. Equity Fund	Class IP GBP (D)	15.77%
Iridian U.S. Equity Fund	Class I USD (D)	19.25%
Iridian U.S. Equity Fund	Class I GBP (A)	15.52%
Iridian U.S. Equity Fund	Class I GBP (D)*	-
Iridian U.S. Equity Fund	Class Y USD (A)*	-
Iridian U.S. Equity Fund	Class Z USD (A)	19.33%
Iridian U.S. Equity Fund	Class A GBP (D)	16.19%
		Since Inception
Sub-Fund	Share class	Performance %
Iridian U.S. Equity Fund	Class I USD (A)	62.36%
Iridian U.S. Equity Fund	Class IP USD (A)	58.33%
Iridian U.S. Equity Fund	Class IP EUR (D)*	=
Iridian U.S. Equity Fund	Class IP GBP (D)	25.99%
Iridian U.S. Equity Fund	Class I USD (D)	44.68%
Iridian U.S. Equity Fund	Class I GBP (A)	63.38%
Iridian U.S. Equity Fund	Class I GBP (D)*	-
Iridian U.S. Equity Fund	Class Y USD (A)*	-

Historical performance is no indicator for current or future performance. The performance data does not take account of any commissions and costs charged when subscribing or redeeming units.

41.48%

16.19%

Class Z USD (A)

Class A GBP (D)\*\*

<sup>\*</sup>Class IP EUR (D), Class I GBP (D) and Class Y USD (A) were completely redeemed during the year ended 31 December 2020.

<sup>\*\*</sup>Class A GBP (D) was launched during the year ended 31 December 2020.

### APPENDIX II (UNAUDITED)

# **INVESTMENT MANAGER REMUNERATION DISCLOSURES** For the financial year ended 31 December 2020

Reference is made to the European Communities (Undertakings for Collective Investment in Transferable Securities) Regulations 2011 (as amended) (the "UCITS Regulations") and specifically the remuneration requirements set out in Regulations 24A and 24B thereof. The Company, as a self-managed investment company, has implemented a remuneration policy in line with the provisions of Regulation 24A ("Remuneration Policy").

The European Securities and Markets Authority ("ESMA") was mandated under Article 14a(4) of Directive 2009/65/EC (as amended) (the "UCITS Directive") to produce guidance on the application of remuneration principles under Article 14b. ESMA issued the 'Guidelines on sound remuneration policies under the UCITS Directive and AIFMD' (the "ESMA Guidelines") on 31 March 2016, and the ESMA Guidelines have applied since 1 January 2017 to UCITS management companies, self-managed entities such as the Company, and, to the extent applicable, its delegate(s).

Regulation 89(3A) of the UCITS Regulations requires the annual report of the Company to contain certain remuneration-related information, and this requirement applied as of 18 March 2016.

In the financial year of the Company ended on 31 December 2020:

- (a) Only fixed remuneration (meaning payments or benefits without consideration of any performance criteria) is paid by the Company to the two independent Directors and to a governance service provider of the Company who fulfil managerial functions. The other two Directors who are executives of the Investment Manager are not paid such remuneration. The Directors of the Company, as identified in the section of the Prospectus headed "Directory", are responsible for awarding remuneration and any benefits, and these are set at a level that reflects the qualifications and contribution required taking into account the Company's size, internal organisation and the nature, scope and complexity of its activities.
- (b) Director's fees charged for the year amounted to \$55,085.
- (c) The Remuneration Policy was subject to an annual review in accordance with the requirements of the UCITS Regulations and amended as described below.
- (d) The Remuneration Policy was updated to reflect the publication of the ESMA Guidelines.

The Company delegates certain portfolio management activities for the Iridian UCITS Fund plc to the Investment Manager (the "Delegate").

The Delegate has calculated that, in aggregate, it pays its relevant staff the following in relation to the functions it performs in respect of the Company:

An aggregate amount of \$98,200 including an amount of \$0 corresponding with received performance fees. This amount is applied across three members of staff at the Delegate and is apportioned as approximately 27% in aggregate fixed remuneration and 73% in aggregate variable remuneration.

In accordance with applicable European regulation and guidance, these figures are calculated on the basis of fee income received by the Delegate in relation to the Company and how this correlates with the relevant staff's remuneration. Further, these figures relate only to the proportion of the relevant staff's remuneration that is estimated to be attributed, on a pro rata basis, to the functions such staff performs for the Delegate in relation to the Company.